BLAINJECTIONINJECTABLE
Approved
Nov 2019
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 2d ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ABRILADA (adalimumab-afzb) is a monoclonal antibody (mAb) biosimilar approved by FDA in November 2019 as a follow-on biologic to Humira (adalimumab). It is indicated for multiple autoimmune and inflammatory conditions including rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. The drug works by binding TNF-alpha to reduce inflammatory signaling in immune-mediated diseases.
Peak
As a peak-stage biosimilar in a competitive 30-point pressure market, the product is at high volume but faces pricing and share defense challenges that drive substantial commercial team activity.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ABRILADA roles emphasize commercial execution and payer engagement in a competitive biosimilar environment rather than clinical development or regulatory work. Professionals on this team navigate pricing pressure, formulary access, and share-of-voice strategies in a mature market dominated by the originator and competing biosimilars.
Brand ManagerMarket Access Manager
Worked on ABRILADA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.